Food and Drug Administration (cisplatin, carboplatin, and oxaliplatin), has prompted over the years an intense research activity aiming to identify new metal-based anticancer drugs with enhanced efficacy, lower toxicity, and a broader spectrum of activity [1,2].
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}